Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Research article

Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews

Lisa V Adams1*, Elizabeth A Talbot1, Karen Odato2, Heather Blunt2 and Karen R Steingart3

Author Affiliations

1 Infectious Disease and International Health Section, Department of Medicine, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH 03755, USA

2 Biomedical Libraries, Geisel School of Medicine at Dartmouth, 37 Dewey Field Road, Hanover, NH 03755, USA

3 Cochrane Infectious Diseases Group, Liverpool, UK

For all author emails, please log on.

BMC Infectious Diseases 2014, 14:281  doi:10.1186/1471-2334-14-281

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2334/14/281


Received:26 April 2014
Accepted:14 May 2014
Published:21 May 2014

© 2014 Adams et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

Background

Uptake of isoniazid preventive therapy (IPT) to prevent tuberculosis has been poor, particularly in the highest risk populations. Interventions to improve IPT delivery could promote implementation. The large number of existing systematic reviews on treatment adherence has made drawing conclusions a challenge. To provide decision makers with the evidence they need, we performed an overview of systematic reviews to compare different organizational interventions to improve IPT delivery as measured by treatment completion among those at highest risk for the development of TB disease, namely child contacts or HIV-infected individuals.

Methods

We searched the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE), and MEDLINE up to August 15, 2012. Two authors used a standardized data extraction form and the AMSTAR instrument to independently assess each review.

Results

Six reviews met inclusion criteria. Interventions included changes in the setting/site of IPT delivery, use of quality monitoring mechanisms (e.g., directly observed therapy), IPT delivery integration into other healthcare services, and use of lay health workers. Most reviews reported a combination of outcomes related to IPT adherence and treatment completion rate but without a baseline or comparison rate. Generally, we found limited evidence to demonstrate that the studied interventions improved treatment completion.

Conclusions

While most of the interventions were not shown to improve IPT completion, integration of tuberculosis and HIV services yielded high treatment completion rates in some settings. The lack of data from high burden TB settings limits applicability. Further research to assess different IPT delivery interventions, including those that address barriers to care in at-risk populations, is urgently needed to identify the most effective practices for IPT delivery and TB control in high TB burden settings.

Keywords:
Tuberculosis; HIV; Adherence; Latent tuberculosis infection

Background

Treating latent tuberculosis infection (LTBI) with isoniazid preventive therapy (IPT) in persons who are at high risk for developing tuberculosis (TB) has been shown to decrease progression to TB disease and improve survival [1-4]. Consequently, the World Health Organization recommends a six-month course of IPT for children younger than five years who are close contacts to an adult with sputum smear-positive TB, and HIV-infected adults and children older than 12 months who are unlikely to have TB disease [5].

Despite clear international recommendations, only 8% to 20% of eligible children actually receive IPT [6]. Studies in HIV-infected populations show similarly low rates of IPT provision [7,8]. Possible reasons for this low uptake include imperfect TB/HIV care coordination for many HIV-infected IPT candidates and a past focus on TB disease diagnosis rather than prevention. There is also a lack of programmatic guidelines to identify IPT candidates, sensitive methods to exclude TB disease, and patient management tools to ensure LTBI treatment completion. Even if patients are initiated on IPT, benefit is only realized if patients complete their prescribed therapy. While barriers to IPT adherence can exist at both programmatic and patient levels, TB control programs have long recognized the need to move beyond specific patient factors and encompass broader health system changes to optimize individual patient care and outcomes.

Medication adherence is a complex human behavior, and the medical and social science literature on this topic is extensive. In such cases – where hundreds of published studies exist on an issue – systematic reviews are typically performed to formulate precise questions and to consolidate, appraise and evaluate the evidence to facilitate decision making by clinicians and policy makers. In the case of treatment adherence, several systematic reviews have examined the effectiveness of different interventions to improve adherence in various medical conditions [9-14], including tuberculosis [15,16]. Some reviews have focused on a specific intervention with patients, such as counseling and patient education [12-15], while others have looked at system changes in regimen schedules and pill packaging [11]. Several recent systematic reviews have focused on interventions specifically to improve IPT adherence, such as the use of lay health workers [9], patient education and counseling [15], and incentives and enablers [16].

Given the many strategies that could potentially improve medication adherence, determining the attributable effects and summarizing the findings of the many studies that have evaluated these different strategies would be difficult. To provide focus, in their overview of reviews, van Dulmen and colleagues have described theoretical approaches to adherence and categorized interventions on patient adherence for different medical conditions [17]. The authors define seven categories of adherence interventions: technical (e.g., changes in packaging), behavioral (e.g., use of reminders), educational (e.g., providing information to individual patients), affective (e.g., provider empathy), social support (e.g., practical or emotional support), structural (e.g., establishing a care program in the workplace) and complex or multi-faceted (e.g., some combination of the above) [17]. With treatment completion serving as our patient important outcome, we sought interventions in IPT delivery most likely to improve adherence among individual patients.

Interventions related to the delivery, practice, and organization of health care services have also been categorized by the Cochrane Effective Practice and Organisation of Care (EPOC) Group [18]. Under the EPOC taxonomy, the category “organizational interventions” are those interventions that involve “a change in who delivers health care, how care is organized, or where care is delivered” [18]. This category of interventions fits a health system’s approach to support adherence. With treatment completion as the ultimate goal of IPT delivery, organizational interventions that can be undertaken by a national TB program to affect IPT adherence may have the greatest impact. Mapping interventions to the EPOC group taxonomy ensures valid comparisons of findings are made.

With the large number of systematic reviews already performed on interventions to improve treatment adherence generally and IPT adherence specifically, the challenge persists of how to integrate, assess, compare and contrast the evidence from these reviews to facilitate clinical and programmatic decision-making. In this instance, the best approach is to summarize the reviews in one place by performing an overview of systematic reviews. As described by Smith et al., overviews of systematic reviews are the appropriate next step to provide clinical decision makers with the comprehensive information that they need [19].

Therefore, we conducted an overview of systematic reviews that assessed interventions to improve adherence of IPT in high-risk individuals to better inform decision making on IPT delivery. Specifically, we sought to compare different organizational interventions to improve IPT delivery as measured by treatment completion among those at highest risk for the development of TB disease, namely child contacts or HIV-infected individuals. This focused review question allowed us to concentrate on interventions that a national TB program can most easily influence. To the best of our knowledge, no such overview has been performed. These findings are intended to inform public health professionals and policy makers from high TB burden countries where IPT delivery by programs, uptake by patients, and treatment completion rates are suboptimal. Improved worldwide delivery of IPT could reduce global morbidity and mortality from TB, especially among children and HIV-infected individuals.

Objective

Our objective was to synthesize and compare the evidence from systematic reviews examining the effect of organizational interventions on IPT delivery among those at highest risk for the development of TB disease.

Methods

We followed the Cochrane Collaboration recommendations for performing overviews of systematic reviews as described in the Cochrane Handbook [20].

Criteria for considering reviews for inclusion

Types of reviews: We included all systematic reviews written in English, Spanish, and French that met our selection criteria and were identified by our search strategies. We excluded narrative reviews and systematic reviews that did not include acceptable study designs (i.e., randomized controlled trials, quasi-randomized controlled trials, controlled before-and-after studies, interrupted time series or before-and-after studies); and evaluate at least one of the specified organizational interventions; or measure treatment completion.

Types of participants: Although our population of interest was child contacts and HIV-infected individuals, we included systematic reviews of all persons for whom treatment of LTBI is recommended regardless of age and HIV infection [21,22]. We broadened inclusion because we anticipated there would be limited data on child contacts and HIV-infected individuals. We included systematic reviews that focused primarily on organizations and health systems.

Types of interventions

Interventions related to the delivery, practice, and organization of health care services have been categorized into four groups by the Cochrane Effective Practice and Organisation of Care (EPOC) Group: professional, financial, organizational, and regulatory [18]. We selected organizational interventions because these are the interventions most feasible for TB control program implementation, can be instituted without the need for considerable additional financial inputs, and are expected to be the most commonly practiced and studied interventions to improve IPT delivery. We included one provider-oriented intervention, the revision of professional roles, since this also seemed a feasible activity for a national TB program to undertake. Other types of interventions are not typically under the purview of the TB control program. The organizational, predominantly structural, interventions we considered most relevant to IPT delivery are listed in Table  1. We included reviews evaluating these interventions, or combinations of these interventions. We excluded financial and regulatory interventions.

Table 1. Mapping of the included reviews to the selected cochrane effective practice and organisation of care group organizational interventionsa

Types of outcomes

The primary outcome of interest was treatment completion rate (TCR). We defined TCR as the percentage of patients who initiated IPT and took at least 80% of prescribed doses within a nine-month period. We also included TCR as defined by the authors of the review. IPT was defined as INH monotherapy taken at any dose for at least six months to treat LTBI.

Search strategy

We searched the following databases without date restrictions on August 15, 2012: the Cochrane Database of Systematic Reviews (Cochrane Library 2012 issue 8), the Database of Abstracts of Reviews of Effects (DARE) (Cochrane Library 2012 issue 8) and MEDLINE (PubMed). To identify systematic reviews in MEDLINE, we used PubMed's Systematic Review filter. We searched for citations in all languages; however, due to available resources, we restricted the articles for inclusion to those published in English, French, or Spanish.

We employed two search strategies (Additional file 1): the first included indexed terms and text words related to latent tuberculosis and its drug therapies. Due to the similarities between IPT and co-trimoxazole for primary prevention of opportunistic infections in HIV-infected persons in terms of duration and target population, we also searched for systematic reviews that evaluated the delivery of co-trimoxazole preventive therapy. Therefore, the second strategy included indexed terms and text words related to HIV, pneumocystis pneumonia, and co-trimoxazole preventive therapy. Additionally, one author hand-searched reviews and overviews in four Cochrane review groups (Cochrane Infectious Diseases Group, Cochrane Effective Practice and Organisation of Care Group, Cochrane Public Health Group, Cochrane Consumers and Communication Review Group) and DARE databases through June 2012. We also checked reference lists of selected papers for additional reviews.

Additional file 1. Search strategy.

Format: DOCX Size: 91KB Download fileOpen Data

Selection of reviews

Two authors independently scrutinized non-duplicate titles and abstracts identified by literature searching to identify potentially eligible reviews. Any citation identified by either author was included in a second screen during which the full text was reviewed. The same review authors independently assessed the reviews for inclusion using pre-specified inclusion and exclusion criteria. Any disagreements were resolved by discussion. One review author selected reviews identified by hand-searching the Cochrane database.

Data collection and analysis

We developed a standardized data extraction form to summarize key characteristics of the reviews. One author piloted the form with two reviews and finalized the form. Then two authors independently extracted data on the following characteristics: objectives, study designs of included studies, participants, setting, country, interventions, outcomes, and review quality. Any disagreements in data extraction were resolved by discussion or decision of a third author. We did not contact review or study authors for additional information due to resource constraints.

Quality assessment

We used the AMSTAR instrument to assess methodological quality of each review [29]. We did not assess the quality of the individual studies in the reviews but noted any assessment by the review authors.

Role of the funding source

The funding source for this work did not influence the study design, interpretation of data, writing of the report, or the decision to submit the paper for publication.

Results

Our search yielded a total of 589 citations, with an additional nine systematic reviews identified from a review of the references of the selected reviews and one by hand-searching the Cochrane database. Figure  1 details our search and selection process. We selected reviews that, based on our inclusion criteria, included at least one organizational intervention (based on the EPOC taxonomy) to improve IPT or co-trimoxazole adherence. We identified six reviews that met our criteria. All assess IPT delivery; none of the co-trimoxazole adherence reviews identified met our intervention criteria.

thumbnailFigure 1. PRISMA Flow Diagram. Legend: The PRIMSA diagram details our search and selection process applied during the overview.

Of the six selected reviews (involving a total of 105 studies), one was a Cochrane review [9] and five were non-Cochrane reviews [23-27]. The specific interventions in this overview mapped to the EPOC taxonomy are presented in Table  1. Extracted data from the six included reviews are shown in Table  2.

Table 2. Characteristics of included reviews

The six systematic reviews assessed different interventions to improve IPT adherence and, in some cases, adherence with diagnostic testing and other treatments. Hirsch-Moverman et al. also aimed to identify predictors of adherence and Zuñiga et al. to identify correlates of IPT adherence in Hispanic patients. In assessing these two reviews, we focused on the effect of the interventions. Four of the six reviews assessed studies of IPT adherence that were conducted predominantly in the US [9,23,26,27], or the US and Canada [26], or the US, Spain (four studies) and Singapore (one study) [23], the latter being a high-income country with a TB incidence rate of 50/100,000 [30]. The most common study designs reported by the review authors were observational (30 studies), randomized controlled trials (19 studies), and prospective cohort (15 studies).

The AMSTAR ratings of the included reviews ranged from 4 to 10 out of a maximum of 11 (Table  3). Only one review was rated as high quality (AMSTAR score of 10) and three reviews were rated as lower quality (AMSTAR ratings of less than seven). Only two reviews reported on methodological quality of the included studies [9,25]. In Lewin et al., two of 82 studies addressed IPT delivery; the review authors judged that one of these studies had adequate sequence generation but was not blinded. The other study only addressed incomplete data adequately. Neither study had sufficient data for the review authors to determine the risk of bias due to allocation concealment or freedom from selective reporting. In Uyei et al., the authors’ general appraisal of the quality of studies noted the absence of randomization and that missing data were addressed in only two of the included studies.

Table 3. AMSTAR rating for included systematic reviews

Participants

All six reviews assessed studies that enrolled adults, and two reviews included children or adolescents (1 of 5 [20%] studies in Defulio et al. and 1 of 4 [25%] in Lewin et al.). Studies of IPT adherence in the US were focused on the populations that are at the highest risk for treatment non-adherence, namely intravenous drug users [9,23,24,26], incarcerated individuals [9,24,27], homeless individuals [23,27], and recent immigrants [24,25]. Three reviews specified that HIV-infected individuals were included in any of the included studies (9 of 18 [50%] studies in Al-Darraji et al., 9 of 78 [12%] in Hirsch-Moverman and 56 of 56 [100%] in Uyei et al.) [23,25,26].

Interventions

The majority of interventions examined in the studies of the included systematic reviews were changes in the setting/site of service delivery. Three reviews assessed studies of integration of IPT delivery into other health care services, either community-based care [23,24] or HIV care [25]. One review assessed studies that examined the impact of a revision of professional roles, specifically the use of lay health workers to support self-administered IPT or provide directly observed therapy [9]. Two reviews assessed the impact of providing directly observed therapy [26,27], while one also looked for additional correlational relationships related to side-effects, social support, demographics, education, and self-report of health [27].

Outcomes

Most reviews reported outcomes related to IPT adherence and TCR (Table  2). Only one review provided a clear definition of treatment completion, defining it as the ingestion of at least 80% of prescribed doses [25]. The authors of this review stated that, to allow comparisons across studies, they calculated TCR as the number completing treatment over the number initiating treatment. Another review calculated TCR as the percentage of patients who completed “six months of treatment within the study’s follow-up period” [25]. Most reviews provided only the post-intervention TCR (i.e., without the pre-intervention rate). Collectively, there was little evidence to demonstrate that most of the interventions studied had a positive impact on TCRs.

Discussion

This overview is the first published assessment of the evidence of organizational interventions to improve IPT adherence. Among the reviews that assessed studies of IPT adherence in high-risk US populations, none of the interventions examined were found to be effective at improving IPT adherence or TCR. The systematic review by Uyei et al. that included only studies from high TB-burden, low-income settings examined the impact of TB and HIV service integration. While IPT adherence was reportedly high across the six studies in this review, the TCRs were variable. In addition, the lack of comparison groups in these studies makes it difficult to assess if TB and HIV service integration was the main driver of the benefit.

Beyond setting, the applicability of the evidence from these systematic reviews based on patient population is uncertain. While our populations of interest were child contacts and HIV-infected individuals, most reviews assessed IPT adherence in adult populations, with only two reviews including children in no more than one-quarter of their included studies [9,24]. Similarly, only three reviews included HIV-infected persons, although with greater representation among the included studies (12% - 100%) [23,25,26].

We found that the quality of the systematic reviews in this overview varied. The low quality of the majority of reviews suggests limitations in design and/or execution that may undermine conclusions about the results of the reviews.

We also recognize that there are other as yet unstudied interventions or combinations of interventions that might improve IPT adherence. In their overview of reviews of interventions focused on improving consumers’ use of non-IPT medication, Ryan et al. examined self-monitoring and self-management, simplification of dosing, and involvement of pharmacists [31]. While they found several interventions that showed promise in improving adherence, none were consistently effective across diseases, populations, or settings. It is unclear whether their findings are applicable to IPT because none of the reviews they evaluated specifically addressed IPT.

Although the contribution of educational and counseling sessions to adherence was not the primary objective of this overview, we extracted these data when available. Two reviews that met inclusion for our overview (that were not included in Ryan et al.) assessed the use of education and/or counseling as a means of improving treatment adherence in a number of settings [23,26]. Both included studies of IPT delivery but neither found a demonstrable improvement in adherence.

A recent Cochrane review by M’Imunya et al. specifically assessed the role of patient education and counseling in promoting adherence to TB treatment and LTBI treatment [15]. They conclude that the LTBI TCR may increase, but they emphasize that benefits from patient education and counseling vary with context and the underlying reasons for poor adherence. Therefore, any educational intervention must be tailored to the setting and population, and there is unlikely to be a universally beneficial approach.

We also recognize that adverse reactions and how they are managed are important to patients and can reduce adherence and treatment completion. Adverse reactions and their impact on treatment completion could not be systematically addressed in our overview as this would have required a different methodology. Nonetheless, we looked for and summarized adverse drug reactions when data were provided in the included reviews. While four of the six review authors sought to collect this data, only two reported any data on the frequency of adverse events. In both reviews, the reported rates were very low (median <5%) [23,27].

There are limitations to our overview. While the search strategy included all languages, we included only reviews published in English, French, and Spanish, and therefore may have missed papers that were published in other languages. However, of 589 citations initially identified, only 25 (4%) papers were excluded based on language. There was some overlap across the reviews that examined specific populations, namely US residents who were homeless, using intravenous drugs, and/or in prison (8 of 105 total studies [8%] appeared in more than one review). One study of Hispanic patients was included in two reviews (1/105, 1%).

Conclusions

Overall, while most organizational interventions did not consistently result in improvements in IPT completion, the integration of TB and HIV services yielded high TCRs in some settings. The lack of data on organizational interventions to improve IPT delivery in high burden TB settings and in the high-risk populations of interest makes it difficult to draw conclusions applicable to populations in these settings. This notable absence of data is, however, a clear indication of the need for additional investigation in these settings and these populations. Further research to assess different IPT delivery interventions, including those that address barriers to care in at-risk populations, is urgently needed to identify the most effective practices for IPT delivery and TB control in high TB-burden settings.

Abbreviations

DARE: Database of Abstracts of Reviews of Effects; EPOC: Effective Practice and Organisation of Care; IPT: Isoniazid preventive therapy; LTBI: Latent tuberculosis infection; TB: Tuberculosis; TCR: Treatment completion rate.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

LVA, EAT, and KRS developed the study design. KO and HB led development of the search strategy and conducted the searches of the different databases. LVA, EAT, and KRS developed the criteria for evaluating the systematic reviews including inclusion/exclusion criteria. LVA and EAT screened the reviews identified and selected those included. LVA, EAT, and KRS interpreted the findings. All authors contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Authors’ information

KRS is an Editor with the Liverpool-based Cochrane Infectious Diseases Group, which aims to impact policy and research in tropical diseases by producing high quality, relevant, systematic reviews and to lead developments in review quality improvement and effective dissemination of findings (http://cidg.cochrane.org/ webcite).

Acknowledgements

The authors wish to thank Alain Mayhew, Managing Editor, the Cochrane Effective Practice and Organisation of Care Group, Ottawa, for his helpful technical review and insightful comments and Paul Garner, Coordinating Editor, Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, for his guidance in structuring an overview of systematic reviews. We also wish to thank Vittoria Lutje, Information Specialist, Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, for her help with the search strategy and Erin Klein, Dartmouth College student, class of 2013, for her assistance with background research. Support for this work was provided by TB CARE II, which is funded by the United States Agency for International Development (USAID) under Cooperative Agreement Number AID-OAA-A-10-00021. The project team includes prime recipient, University Research Co., LLC (URC), and sub-recipient organizations Jhpiego, Partners in Health, Project HOPE along with the Canadian Lung Association; Clinical and Laboratory Standards Institute; Geisel School of Medicine at Dartmouth: The Section of Infectious Disease and International Health; Euro Health Group; and The New Jersey Medical School Global Tuberculosis Institute. The funding source for this work did not influence the study design, interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication.

References

  1. Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons.

    Cochrane Database Syst Rev 2010, 1:CD000171. PubMed Abstract | Publisher Full Text OpenURL

  2. Curry FJ: Prophylactic effect of isoniazid in young tuberculin reactors.

    N Engl J Med 1967, 277:562-567. PubMed Abstract | Publisher Full Text OpenURL

  3. Hsu KH: Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children.

    JAMA 1974, 229:528-533. PubMed Abstract | Publisher Full Text OpenURL

  4. Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E: Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.

    Thorax 2013, 68(3):247-255. PubMed Abstract | Publisher Full Text OpenURL

  5. World Health Organization: Guidance for national tuberculosis programmes on the management of tuberculosis in children – 2nd ed.. Geneva: World Health Organization; 2014.

    http://www.who.int/tb/challenges/childhood_tb_informationsheet.pdf webcite

    OpenURL

  6. van Wyk SS, Reid AJ, Mandalakas AM, Enarson DA, Beyers N, Morrison J, Hesseling AC: Operational challenges in managing Isoniazid Preventive Therapy in child contacts: a high-burden setting perspective.

    BMC Public Health 2011, 11:544. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  7. Bristow CC, Larson E, Vilakazi-Nhlapo AK, Wilson M, Klausner JD: Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa.

    Int J Tuberc Lung Dis 2012, 16(8):1020-1022. PubMed Abstract | Publisher Full Text OpenURL

  8. Chehab JC, Vilakazi-Nhlapo K, Vranken P, Peters A, Klausner JD: Survey of isoniazid preventive therapy in South Africa, 2011.

    Int J Tuberc Lung Dis 2012, 16(7):903-907. PubMed Abstract | Publisher Full Text OpenURL

  9. Lewin S, Munabi Babigumira S, Glenton C, Daniels K, Bosch Capblanch X, Van Wyk BE, Odgaard Jensen J, Johansen M, Aja GN, Zwarenstein M, Scheel IB: Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases.

    Cochrane Database Syst Rev 2010, (3):CD004015.

    doi:10.1002/14651858.CD004015.pub3

    OpenURL

  10. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance.

    Clin Ther 2001, 23:1296-1310. PubMed Abstract | Publisher Full Text OpenURL

  11. Dodds F, Rebair-Brown A, Parsons S: A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication.

    Clin Effect Nurs 2000, 4:47-53. Publisher Full Text OpenURL

  12. Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, Kimber A, Shaw K, Walker J: Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review.

    Health Technol Assess 2001, 5:1-79. OpenURL

  13. Sharp J, Wild MR, Gumley AI: A systematic review of psychological interventions for the treatment of nonadherence to fluid-intake restrictions in people receiving hemodialysis.

    Am J Kidney Dis 2005, 45:15-27. PubMed Abstract | Publisher Full Text OpenURL

  14. Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F: Improving adherence to antidepressants: a systematic review of interventions.

    J Clin Psychiatry 2003, 64:1415-1420. PubMed Abstract | Publisher Full Text OpenURL

  15. M’Imunya JM, Kredo T, Volmink J: Patient education and counselling for promoting adherence to treatment for tuberculosis.

    Cochrane Database Syst Rev 2012, (5):CD006591.

    doi:10.1002/14651858.CD006591.pub2

    OpenURL

  16. Lutge EE, Wiysonge CS, Knight SE, Volmink J: Material incentives and enablers in the management of tuberculosis.

    Cochrane Database Syst Rev 2012, 1:CD007952. PubMed Abstract | Publisher Full Text OpenURL

  17. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J: Patient adherence to medical treatment: a review of reviews.

    BMC Health Serv Res 2007, 7:55. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  18. Cochrane Effective Practice and Organisation of Care Review Group, Data Collection Checklist. 2002.

    http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf webcite

    OpenURL

  19. Smith V, Devane D, Begley CM, Clarke M: Methodology in conducting a systematic review of systematic reviews of healthcare interventions.

    BMC Med Res Methodol 2011, 11(1):15. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  20. Becker LA, Oxman AD, Chapter 22: Overviews of reviews.

    In Cochrane Handbook for Systematic Reviews of Interventions Edited by Higgins JPT, Green S. 2008. [Version 22.20 22.21 5.0.1 [updated September 2008]. The Cochrane Collaboration]

    http://www.cochrane-handbook.org webcite

    OpenURL

  21. World Health Organization: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011. OpenURL

  22. American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection.

    MMWR Recomm Rep 2000, 49(RR-6):151. OpenURL

  23. Al-Darraji HAA, Kamarulzaman A, Altice FL: Isoniazid preventive therapy in correctional facilities: a systematic review.

    Int J Tuberc Lung Dis 2012, 16(7):871-879. PubMed Abstract | Publisher Full Text OpenURL

  24. DeFulio A, Silverman K: The use of incentives to reinforce medication adherence.

    Prev Med 2012, 55(Suppl):S86-S94. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  25. Uyei J, Coetzee D, Macinko J, Guttmacher S: Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review.

    Lancet Infect Dis 2011, 11(11):855-867. PubMed Abstract | Publisher Full Text OpenURL

  26. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada.

    Int J Tuberc Lung Dis 2008, 12(11):1235-1254. PubMed Abstract | Publisher Full Text OpenURL

  27. Zuñiga JA: Medication adherence in Hispanics to latent tuberculosis treatment: a literature review.

    J Immigr Minor Health 2012, 14(1):23-29. PubMed Abstract | Publisher Full Text OpenURL

  28. Hopkins A, Solomon J, Abelson J: Shifting boundaries in professional care.

    J R Soc Med 1996, 89(7):364-371. PubMed Abstract | PubMed Central Full Text OpenURL

  29. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

    BMC Med Res Methodol 2007, 7:10. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  30. World Health Organization: Global tuberculosis report 2013; WHO report. Geneva: World Health Organization; 2013.

    WHO/HTM/TB/2013.11

    OpenURL

  31. Ryan R, Santesso N, Hill S, Lowe D, Kaufman C, Grimshaw J: Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews.

    Cochrane Database Syst Rev 2011., (5)

    Art. No.: CD007768. doi:10.1002/14651858.CD007768.pub2

    OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/14/281/prepub